Investment objective & strategy
As of April 25, 2025 · prospectusObjective. ProFund VP Pharmaceuticals (the Fund) seeks investment results, before fees and expenses, that track the performance of the S&P Pharmaceuticals Select Industry Index (the Index).
Strategy. The Fund invests in securities that ProFund Advisors believes, in combination, should track the performance of the Index. The Index is designed to measure the performance of pharmaceuticals companies included in the S&P Total Market Index . The S&P Total Market Index is designed to track the broad equity market listed and domiciled in the U.S. The Index includes companies in the pharmaceuticals sub-industry according to the Global Industry Classification Standard ( GICS). These companies are then weighted using an equal weight methodology with liquidity adjustments. The Indexs composition and the assigned weights are reevaluated every September with additional weight adjustments in March , June, and December. The Index is constructed and maintained by S&P Dow Jones Indices LLC. More … The Fund invests in securities that ProFund Advisors believes, in combination, should track the performance of the Index. The Index is designed to measure the performance of pharmaceuticals companies included in the S&P Total Market Index . The S&P Total Market Index is designed to track the broad equity market listed and domiciled in the U.S. The Index includes companies in the pharmaceuticals sub-industry according to the Global Industry Classification Standard ( GICS). These companies are then weighted using an equal weight methodology with liquidity adjustments. The Indexs composition and the assigned weights are reevaluated every September with additional weight adjustments in March , June, and December. The Index is constructed and maintained by S&P Dow Jones Indices LLC. More information about the Index can be found using the Bloomberg ticker symbol SPSIPH. Under normal circumstances, the Fund will invest at least 80% of its total assets in components of the Index or in instruments with similar economic characteristics. The Fund will invest principally in the securities listed below. ? Equity Securities Common stock issued by public companies. ProFund Advisors uses a mathematical approach to investing in which it determines the type, quantity and mix of investment positions that it believes, in combination, the Fund should hold to produce returns consistent with its investment objective. The Fund seeks to remain fully invested at all times in financial instruments that, in combination, provide exposure consistent with the investment objective, without regard to market conditions, trends or direction. The Fund may also invest in or gain exposure to only a representative sample of the securities in the Index or to securities not contained in the Index or in financial instruments, with the intent of obtaining exposure consistent with the investment objective. Please see Investment Objectives, Principal Investment Strategies and Related Risks in the Funds Prospectus for additional details.
Top holdings
As of March 31, 2026 · N-PORT| Security | Ticker | Value | % of fund |
|---|---|---|---|
| ENLIVEN THERAPEUTICS INC | — | $239.16K | 2.35% |
| CORCEPT THERAPEUTICS INC | — | $223.76K | 2.20% |
| TERNS PHARMACEUTICALS INC | — | $211.09K | 2.08% |
| PERRIGO CO PLC | — | $205.05K | 2.02% |
| AXSOME THERAPEUTICS INC | — | $198.43K | 1.95% |
| INNOVIVA INC | — | $194.65K | 1.91% |
| MERCK & CO | — | $193.91K | 1.91% |
| PFIZER INC | — | $192.63K | 1.89% |
| ROYALTY PHARMA-A | — | $192.41K | 1.89% |
| ELANCO ANIMAL HEALTH INC | — | $191.13K | 1.88% |
Portfolio moves
Dec 31, 2025 → Mar 31, 2026How many positions this fund opened, exited, grew, trimmed, or left unchanged between its two most recent N-PORT snapshots — net changes between point-in-time reports, not a trade log.
Similar funds
Funds whose portfolios most overlap this one, by weight| Fund | Overlap | Net exp. |
|---|---|---|
| State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF · XPH | 85% | 0.35% |
| PHARMACEUTICALS ULTRASECTOR PROFUND · PHPIX, PHPSX | 75% | 1.78% |
| Direxion Daily Pharmaceutical & Medical Bull 3X Shares · PILL | 74% | 0.97% |
Advisers
| Firm | Role |
|---|---|
| ProFund Advisors LLC | Adviser |
Footnotes
- Net assets and holdings count as of March 31, 2026, from the fund's N-PORT filing.
Machine-readable: JSON · Markdown. Programmatic access via the agent surface.